Regeneron Pharma (REGN) PT Raised to $410 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Regeneron Pharma (REGN) PT Raised to $480 at Oppenheimer
February 7, 2019 8:15 AM ESTOppenheimer analyst Hartaj Singh raised the price target on Regeneron Pharma (NASDAQ: REGN) to $480.00 (from $440.00) while maintaining a Outperform rating.
Singh commented, "REGN reported 4Q18 sales/earnings and provided a business update on 02/06. The company's Eylea US (and ex-US) sales were 5-9% above OPCO... More
Regeneron (REGN) Tops Q4 EPS by $1.06, Revenues Beat; Offers FY19 Financial Guidance
February 6, 2019 6:32 AM ESTRegeneron (NASDAQ: REGN) reported Q4 EPS of $6.84, $1.06 better than the analyst estimate of $5.78. Revenue for the quarter came in at $1.93 billion versus the consensus estimate of $1.71 billion.
Fourth quarter 2018 revenues were $1.93 billion, an increase of 22%Fourth quarter 2018 EYLEA® (aflibercept) Injection U.S. net sales increased 11% to $1.08 billion versus fourth quarter 2017Fourth quarter 2018 Libtayo® (cemiplimab-rwlc) Injection U.S. net sales were $15 million in the first three months of launchFourth quarter revenues include a $149 million cumulative catch-up adjustment primarily related to the modification of the Sanofi... More